Venous Thromboembolism Safety Tool Kit

Brenda K. Zierler, PhD, RN, RVT University of Washington

Medication Safety: Tools for Diverse Settings September 10, 2008 8:00 AM – 9:30 AM

VTE Safety Toolkit

- Partnership in Patient Safety Grant
- AHRQ (Agency for Healthcare Research and Policy)
- 2-year grant to improve care for patients at risk for or diagnosed with VTE
 - PI: Brenda Zierler, PhD
 - Co-PI: Gene Peterson, MD

VTE Safety Toolkit- What is It?

- Evidence-based algorithms, guidelines, recommendations, and order sets for preventing, diagnosing, treating and educating patients and providers about VTE
- Educational intervention and compliance training
- Medications heparin, warfarin

Interdisciplinary Clinical Team

Name

*Ann Wittkowsky, PharmD Robb Glenny, MD Paul Hendrie, MD Karen McDonough, MD Kim Cantwell-Gab, BSN Gene Peterson, MD Brenda Zierler, PhD David Flum, MD *Mark Meissner, MD Sylvia McKenzie, RN Seth Wolpin, PhD

Expertise

Toolkit/Cases/anticoagulation Toolkit/Cases/Pulmonary ICU Toolkit/Hematologist **Toolkit/Medicine Consult Toolkit/Patient Education Co-PI/Cases/Administration** Toolkit/Cases/Research Design Consult/Prevention/Surgeon Consult/DVT Diagnosis/Surgeon **QI/Mechanical** Prophylaxis Dashboard/Web Team

VTE Safety Toolkit; AHRQ Patient Safety Grant

Why Study VTE? Epidemiology of VTE

- VTE encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Most common preventable cause of hospital death
- 900,000 Americans suffer VTE each year
 400,000 DVT
 500,000 PE

Epidemiology of VTE

In 300,000 patients, PE proves fatal

- 3rd most common cause of hospital-related deaths in the United States
- Post-thrombotic syndrome will be seen in 800,000 pts.
 - 7% of these individuals will have a severe form of the problem and will become disabled
- Survivors are at risk for recurrence of PE
 - Pulmonary hypertension develops in approximately 30,000 patients who survive their PE

Epidemiology of VTE

 1 of 20 hospitalized medical patients will suffer a fatal PE if they have not received appropriate thrombosis prophylaxis

 50% of the 2 million cases of DVT yearly are "silent"

Risk Factors for VTE

- Determine who should receive prophylaxis
- Every patient at UWMC should be assessed for risk of developing VTE
- Understand contraindications to pharmacologic prophylaxis (heparin, warfarin)
- Offer mechanical prophylaxis when pharmacologic prophylaxis is not safe

VTE Safety Toolkit- Components

- VTE Prophylaxis (focus of today's talk)
- Risk Assessment Tool
- DVT Diagnostic Algorithm
- PE Diagnostic Algorithm
- HIT Assessment
- Heparin nomograms (dosing)
- VTE Treatment Pathway
- DVT Treatment Order Set
- Vascular Lab Requisition
- Neural-axial anesthesia guidelines
- Patient Education (prevention & treatment)

VTE as a Clinical and System Problem

• System Barriers

- Providers are not employees of 450-bed academic medical center
- No standards of practice
- Multiple disciplines treating small numbers of patients (without experience or expertise)
- Prophylaxis is underutilized

PAST EXPERIENCE

- Implementation of DVT pathways
- Reasons for failure
 - Trying to change individual physician behavior
 No culture of safety
 - Lack of systems supports
 - No integrated information system
 - Ownership/turf issues

VTE Prophylaxis

- Every patient should be assessed for risk of developing VTE
- Determine who should receive prophylaxis
- Understand dosing and contraindications to pharmacologic prophylaxis (heparin, warfarin)
- Offer mechanical prophylaxis when pharmacologic prophylaxis is not safe
- Document assessment and prophylaxis plan

Steps in Implementation

- Dedicated Web Site
- Training Modules pilot in winter 2007
- Test interactive cases as educational intervention

 Gather feedback about training (effectiveness, clarity, timeliness, relevance)



This Website contains multiple evidence-based tools called the *VTE Safety Toolkit*, for the prevention, diagnosis, and treatment of venous thromboembolism (VTE).

The development and implementation of the toolkit was funded by the Agency for Healthcare Research and Quality (AHRQ) for the purpose of increasing the implementation of safe practice interventions for patients at risk for or who are diagnosed with VTE, through use of an evidenced-based and system-supported interactive **VTE Safety Toolkit**.


DEDICATION

This project is dedicated to the late Dr. D. Eugene Strandness, Jr., MD, who was a Professor of Medicine at the University of Washington School of Medicine. Dr. Strandness had consecutive NIH funding for 15 years studying the natural history of venous thromboembolism. He was an outstanding clinical researcher, mentor, friend and colleague.

UNIVERSITY OF WASHINGTON

	VTE	VENOUS THROMBOEM	BOLISM	CONTACT US AHRG SITE
HOME	TOOLKIT	PATIENT EDUCATION		FERENCES DEVELOPERS
	Screening Diagnostic	a Guidelines & Assessment Algorithms	REVENTION	JUIDLINES
ß		ment Pathways lation Management	or Adults	
	Anticoagu	lation Guidlines For N	euraxial Procedures	

© COPYRIGHT 2006



Copyright: This website is copyrighted. By using this website you agree to abide by copyright laws and the terms of use. Users are granted a limited license to use the site. No part of the site may be reproduced or sold in any form, or by any means, without written permission from the copyright owner. However, information contained in the website can be printed and used by University of Washington faculty, staff and students; clinical and academic faculty from outside universities or healthcare systems, patients or caregivers of patients, and for educational purposes.

Terms of Use: Information on this website is provided "as is" and "as available" basis without any warranty of any kind, either expressed or implied. The University of Washington, the Department of Pharmacy Services, and the University of Washington Medical Center Anticoagulation Services, the School of Nursing EXPRESSLY DISCLAIMS ALL WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTY OF MERCHANTABILITY AND THE IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE. The University of Washington SHALL NOT IN ANY WAY BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR OTHER DAMAGES ARISING OUT OF USE OF OR INABILITY TO USE THIS WEB SITE OR THE INFORMATION IT CONTAINS

Questions & Comments

UNIVERSITY OF WASHINGTON	
V V V ENOUS THROMROEMROLISM	CONTACT US AHRQ SITE
HOME TOOLKIT PATIENT EDUCATION PHYSICIAN COMMUNICATION LINKS REFERENCES	
UW VTE risk assessment and prophylaxis order set	
UWMC vascular diagnostic service (Vascular Lab Requisition)	

CUPYRIGHT 2006

FUNDED BY AFHU

UNIVERSI	TY OF WASH	NGTON		
	VTE	VENOUS THROMBOEMBOLISM		ITACT US RQ SITE
HOME	TOOLKIT	PATIENT EDUCATION PHYSICIAN COMMUNICATION LINK	Server and the server of the s	DEVELOPERS
		DIAGNOSTIC A	LGORI	THMS
ß	<u>Diagnosti</u>	Workup for Patients Presenting with Signs and Symptor	ns of DVT	
Ľ	Diagnosti	Workup for Patients Presenting with Signs and Symptor	ns of PE	
1				
© COPYRI	IGHT 2006		FUNDED	BY AHRO



UNIVERS	ITY OF WASHINGTON	
	VTE VENOUS THROMBOEMBOLISM	CONTACT US AHRQ SITE
HOME	TOOLKIT PATIENT EDUCATION PHYSICIAN COMMUNICATION LINKS REFEREN	
	ANTICOAGULATION MANAG	GEMENT
	Optimal Therapeutic Range and Duration of Anticoagulation	
	Flexible Initiation Methods for Warfarin	
	Dosing Adjustment Nomogram for Warfarin	
Ľ	Recommendations for the Frequency of Monitoring Warfarin	
D	Clinical Management of Suspected HIT	
1		

© COPYRIGHT 2006

UNIVERSITY OF WASHINGTON

CONTACT US AHRQ SITE
REFERENCES DEVELOPERS
FOLICATION
LDUGATION
EDUCAT

Outpatient Treatment Protocol

Patient Testimonials

© COPYRIGHT 2006



AHRQ Patient Safety Network http://psnet.ahrq.gov/

University of Washington Anticoagulation Clinic http://uwmcacc.org/

University of Washington Laboratory Medicine Guidelines for Hypercoagulable Workup (go to page 14 for Venous thromboembolism) http://depts.washington.edu/labweb/PatientCare/Clinical/Guides/hemostasis.pdf

Coalition to Prevent Deep Vein Thrombosis http://www.preventdvt.org/

National Consensus Standards for the Prevention and Care of Venous Thromboembolism (including Deep Vein Thrombosis and Pulmonary Embolism) http://www.qualityforum.org/projects/ongoing/vte/default.asp



1. DVT AND PE PREVENTION GUIDELINES FOR ADULTS

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S-400S

2. ANTICOAGULATION GUIDELINES FOR NEURAXIAL PROCEDURES

Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172-197

3. UW VTE Risk Assessment and Prophylaxis Order Set

Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51:70-78.

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S-400S

White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107:14-8

4. UWMC Vascular Diagnostic Service (Vascular Lab Requisition)

Anderson DR, Kovacs MJ, Kovacs G, et al. Combined use of clinical assessment and d-dimer to improve the management of patients presenting to the emergency department with suspected deep vein thrombosis (the EDITED Study). J Thromb Haemost 2003; 1:645-651

Wells PS, Anderson DR, Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. Thromb Haemost 1999; 81:493-497

Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349:1227-1235

5. Diagnostic Workup for Patients Presenting with Signs and Symptoms of DVT

Anderson DR, Kovacs MJ, Kovacs G, et al. Combined use of clinical assessment and d-dimer to improve the management of patients presenting to the emergency department with suspected deep vein thrombosis (the EDITED Study). J Thromb Haemost 2003; 1:645-651

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:338S-400S

Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med 2001; 135:108-111



The work for this website is the culmination of ongoing venous research at the UWMC. The team members for the current AHRQ study include:

University of Washington Clinical and Research Faculty

Brenda K. Zierler, PhD, RN, RVT, Principle Investigator Associate Dean, Technology Innovations in Education and Research brendaz@u.washington.edu

Gene Peterson, MD, PhD, MHA, Co-Principle Investigator Assistant Professor Associate Medical Director for Quality gpeterso@u.washington.edu

Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP Associate Professor <u>akwitt@u.washington.edu</u>

Robb Glenny, MD Professor of Medicine and of Physiology and Biophysics glenny@u.washington.edu

Paul Hendrie, MD, PhD Hematology Division, Acting Instructor phendrie@u.washington.edu

Parnela Mitchell, PhD, CNRN, FAAN Professor Elizabeth S. Soule Professor, Associate Dean for Research, School of Nursing pmitch@u.washington.edu

.....

Frederick Wolf, MD Professor & Chair, Medical Education & Biomedical Informatics wolf@u.washington.edu

Lynne Robins, PhD Associate Professor, Medical Education and Biomedical Informatics <u>lynner@u.washington.edu</u>

Karen A. McDonough M.D. Division of General Internal Medicine kmcdonou@u washington.edu

Mark Meissner, MD

Randomized Controlled Trial


- Test knowledge acquisition about VTE prevention using interactive case studies
- Control Group (passive didactic)
- Experimental Group (interactive case studies with feedback)
- Mandatory training (similar to HIPAA)
- Tracking outcomes by provider (currently tracking pre-intervention data)

UNIVERSITY OF WASHINGTON

VTE	VENOUS THROMBOEMBOLISM	TOOLKIT
		LOGIN
	USERNAME	
	PASSWORD	
	NEW USER CLICK	SUBMIT

Provider will be randomized when they log-in





COPYRIGHT 2006

VTE

VENOUS THROMBOEMBOLISM

Patients Who Do Not Need Prophylaxis

Almost every hospitalized patient should receive VTE prophylaxis.

Those who do NOT need VTE prophylaxis include patients who are fully anticoagulated with:

Warfarin (INR > 2.0), Heparin (aPTT > 60) Low molecular weight heparin (full dose) Direct thrombin inhibitors (bivalirudin, lepirudin, argatroban) Factor Xa inhibitors (fondaparinux)

As long as patients remain fully anticoagulated with these medications during hospital admission, additional VTE prophylaxis is not required

Passive Didactic Training on core principles ow risk patients who are fully ambulatory

Slide 3 of 8 >>

UNIVERSITY OF WASHINGTON

Control Group will take Post test after passive training



COPYRIGHT 2006

UNIVERSITY OF WASHINGTON


VTE

VENOUS THROMBOEMBOLISM

CONTACT US AHRQ SITE

CASE 1

59 year old male who presents to the Emergency Department with new atrial fibrillation. The patient is admitted to the hospital and started on an intravenous heparin drip (70 U/kg bolus, 15 U/kg/hr initial infusion). What is the most appropriate VTE prevention strategy?



Interactive case studies with feedback

COPYRIGHT 2006

VTE

VENOUS THROMBOEMBOLISM

CONTACT US AHRQ SITE

CASE 1

59 year old male who presents to the Emergency Department with new atrial fibrillation. The patient is admitted to the hospital and started on an intravenous heparin drip (70 U/kg bolus, 15 U/kg/hr initial infusion). What is the most appropriate VTE prevention strategy?

Hct: 38	Platelets:	112	INR: 2.2	Creatinine: 2.3
	0	No nee	d for prophylaxis	
	0	 Pharmacologic prophylaxis indicated Mechanical prophylaxis indicated 		
	X •			

This is not the correct answer. This patient will be fully anticoagulated with heparin as a bridge to transition to therapeutic oral anticoagulation for stroke prevention. This therapy is adequate prophylaxis for VTE.


/TE

VENOUS THROMBOEMBOLISM

CONTACT US AHRQ SITE

CASE 1

59 year old male who presents to the Emergency Department with new atrial fibrillation. The patient is admitted to the hospital and started on an intravenous heparin drip (70 U/kg bolus, 15 U/kg/hr initial infusion). What is the most appropriate VTE prevention strategy?



This is the correct answer. This patient will be fully anticoagulated with heparin as a bridge to transition to therapeutic oral anticoagulation for stroke prevention. This therapy is adequate prophylaxis for VTE. VTE

VENOUS THROMBOEMBOLISM

COMPLETION

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

100% pass rate expected; certification will be granted and linked to Quality Improvement (compliance)

IMPLEMENTATION of VTE TOOLKIT

- Systems approach
- Buy-in from Administration
- Focus on patient safety
- Mandatory training to meet core competencies on VTE prophylaxis
- Joint Commission and the National Quality Forum

Conclusion

 Improve patient safety by adopting practice standards based on evidence from the literature

Improve utilization of diagnostic services

Improve safety of medications (heparin nomograms/guidelines)

<u>http://vte.son.washington.edu</u>

VTE Safety Toolkit; AHRQ Patient Safety Grant

Thank You

